Gastrointestinal Over-the-Counter (OTC) Drugs Market Report 2026

The gastrointestinal over-the-counter (otc) drugs market size has grown strongly in recent years. It will grow from $49.59 billion in 2025 to $53.74 billion in 2026 at a compound annual growth rate (CAGR) of 8.4%. The growth in the historic period can be attributed to digestive disorder prevalence, otc drug accessibility, pharmacy retail expansion, urban lifestyle changes, dietary habit shifts.

The gastrointestinal over-the-counter (otc) drugs market size is expected to see strong growth in the next few years. It will grow to $73.3 billion in 2030 at a compound annual growth rate (CAGR) of 8.1%. The growth in the forecast period can be attributed to preventive digestive care adoption, e-commerce growth, clean-label otc demand, aging population, digestive health awareness. Major trends in the forecast period include rising self-medication for digestive disorders, growing demand for fast-acting otc relief, increased use of combination gastrointestinal products, expansion of online pharmacy sales, growing preference for herbal and enzyme-based products.

The increasing prevalence of digestive disorders is expected to drive the growth of the gastrointestinal OTC drugs market going forward. Digestive disorders encompass a range of conditions affecting the gastrointestinal tract, including the stomach, intestines, and associated organs. The rise in digestive disorders is primarily due to higher consumption of processed, low-fiber foods, which disrupt gut health and impair digestion. Gastrointestinal OTC drugs help manage digestive disorder symptoms by reducing stomach acid, regulating bowel movements, and supporting overall gut health. They offer fast and convenient relief from common issues such as acidity, constipation, and indigestion. For instance, in December 2023, according to the IBD Registry Ltd., a UK-based non-profit organization, the number of individuals with inflammatory bowel disease (IBD) exceeded 5,300, marking an increase of more than 3,000 members compared to 2022. Therefore, the increasing prevalence of digestive disorders is driving the growth of the gastrointestinal OTC drugs market.

Major companies operating in the gastrointestinal OTC drugs market are focusing on developing advanced products, such as over-the-counter (OTC) proton pump inhibitors (PPIs), to provide effective and long-lasting relief from acid-related disorders. OTC PPIs are medications available without a prescription that reduce stomach acid production, commonly used to treat conditions like frequent heartburn, gastroesophageal reflux disease (GERD), and gastric ulcers. For instance, in March 2025, Eisai Co., Ltd., a Japan-based pharmaceutical company, received approval in Japan to switch its Pariet S (rabeprazole sodium 10 mg) from prescription (Rx) to OTC status, making it the first OTC PPI in Japan with the same active ingredient and dosage as its prescription counterpart. Pariet S is indicated for stomach pain, heartburn, and bloating, offering 24-hour relief with a once-daily, easy-to-swallow tablet, addressing the growing need for effective acid-related treatments amid lifestyle and demographic changes.

In July 2024, Cooper Consumer Health SAS, a France-based consumer healthcare company, acquired Viatris Inc.’s OTC business for an undisclosed amount. This acquisition allows Cooper Consumer Health to expand its presence across key European markets and double its revenues by adding over 200 well-known OTC brands in therapeutic areas including gastrointestinal care, feminine hygiene, antiseptics, and cholesterol management. Viatris Inc. is a US-based healthcare company specializing in gastrointestinal OTC drugs.

Major companies operating in the gastrointestinal over-the-counter (otc) drugs market are Pfizer Inc., Procter & Gamble Co., Johnson & Johnson, Merck & Co. Inc., Bayer AG, Novartis AG, Sanofi S.A., AstraZeneca plc, Abbott Laboratories, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Reckitt Benckiser Group plc, Boehringer Ingelheim GmbH, Haleon plc, Sandoz AG, Bausch Health Companies Inc., Sun Pharmaceutical Industries Ltd., Perrigo Company plc, Dr. Reddy's Laboratories Ltd.

North America was the largest region in the gastrointestinal over-the-counter (OTC) drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gastrointestinal over-the-counter (otc) drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the gastrointestinal over-the-counter (otc) drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have raised costs in the gastrointestinal OTC drugs market by affecting imports of active ingredients, excipients, and packaging materials. Antacids, laxatives, and anti-diarrheal products are most impacted, especially in Asia-Pacific and North America where global sourcing is common. Retail and online pharmacies experience margin pressure. Positively, tariffs are promoting regional production of digestive health medicines and OTC formulations.

The gastrointestinal over-the-counter (otc) drugs market research report is one of a series of new reports that provides gastrointestinal over-the-counter (otc) drugs market statistics, including gastrointestinal over-the-counter (otc) drugs industry global market size, regional shares, competitors with a gastrointestinal over-the-counter (otc) drugs market share, detailed gastrointestinal over-the-counter (otc) drugs market segments, market trends and opportunities, and any further data you may need to thrive in the gastrointestinal over-the-counter (otc) drugs industry. This gastrointestinal over-the-counter (otc) drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Gastrointestinal over-the-counter (OTC) drugs are non-prescription medications used to prevent or manage common digestive issues. They provide convenient and fast relief for conditions like indigestion, nausea, constipation, or diarrhea, helping maintain digestive comfort and overall gastrointestinal wellness.

The main product types of gastrointestinal OTC drugs include antacids, laxatives, anti-diarrheals, anti-emetics, and others. Antacids work by neutralizing stomach acid to relieve heartburn and indigestion. These drugs are available in various formulations, including tablets, capsules, and liquids, and are used for indications such as heartburn, diarrhea, constipation, gastroesophageal reflux disease (GERD), nausea, vomiting, motion sickness, and more. They are distributed through multiple channels, including direct tender, hospital pharmacies, retail pharmacies, online pharmacies, and others, serving end users such as hospitals, clinics, home healthcare, and general consumers.

The gastrointestinal over-the-counter (OTC) drugs market consists of sales of digestive enzymes, probiotics, stool softeners, and fiber supplements. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.